Loading...
CRBN logo

Corbion N.V.ENXTAM:CRBN Rapport sur les actions

Capitalisation boursière €1.1b
Prix de l'action
€18.82
€24.03
21.7% sous-évalué décote intrinsèque
1Y-0.2%
7D-2.3%
Valeur du portefeuille
Voir

Corbion N.V.

ENXTAM:CRBN Rapport sur les actions

Capitalisation boursière : €1.1b

Corbion (CRBN) Aperçu de l'action

Corbion N.V. fournit de l'acide lactique et des dérivés de l'acide lactique, des solutions de conservation des aliments, des mélanges fonctionnels et des ingrédients à base d'algues aux Pays-Bas, aux États-Unis, en Asie, dans le reste de l'Amérique du Nord, dans le reste de l'Europe, au Moyen-Orient et en Afrique. Plus de détails

CRBN analyse fondamentale
Score flocon de neige
Évaluation5/6
Croissance future1/6
Performances passées4/6
Santé financière5/6
Dividendes3/6

CRBN Community Fair Values

Create Narrative

See what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.

Corbion N.V. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Corbion
Historique des cours de bourse
Prix actuel de l'action€18.82
Plus haut sur 52 semaines€21.64
Plus bas sur 52 semaines€16.16
Bêta0.91
Variation sur 1 mois-1.77%
Variation sur 3 mois-9.95%
Variation sur 1 an-0.21%
Variation sur 3 ans-30.55%
Variation sur 5 ans-62.30%
Évolution depuis l'introduction en bourse-28.08%

Nouvelles et mises à jour récentes

Mise à jour du récit May 09

CRBN: Special Dividend And Higher Future P E Could Support Re Rating

Analysts have reduced their fair value estimate for Corbion from €30.00 to €28.00, citing updated assumptions for revenue growth, profit margins and future P/E following recent research, including the Barclays downgrade. Analyst Commentary Recent research has led to a lower fair value estimate for Corbion, but bullish analysts still highlight several supports for the stock, focusing on how current assumptions around revenue, margins and P/E could play out over time.
Mise à jour du récit Apr 22

CRBN: Special Dividend And Execution On Margins Will Support Upside Potential

The updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.

Recent updates

Mise à jour du récit May 09

CRBN: Special Dividend And Higher Future P E Could Support Re Rating

Analysts have reduced their fair value estimate for Corbion from €30.00 to €28.00, citing updated assumptions for revenue growth, profit margins and future P/E following recent research, including the Barclays downgrade. Analyst Commentary Recent research has led to a lower fair value estimate for Corbion, but bullish analysts still highlight several supports for the stock, focusing on how current assumptions around revenue, margins and P/E could play out over time.
Mise à jour du récit Apr 22

CRBN: Special Dividend And Execution On Margins Will Support Upside Potential

The updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.
Mise à jour du récit Apr 08

CRBN: Raised Fair Value And Barclays Downgrade Will Shape Risk Balance

Analysts now set Corbion's fair value at €19.60, up from €18.60. This reflects updated assumptions on growth, margins and P/E multiples, even as some recent research, including a downgrade at Barclays, highlights ongoing risks.
Mise à jour du récit Mar 24

CRBN: Higher Margins And Special Dividend Will Support Future Re Rating

Analysts have maintained their price target for Corbion at €30.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the main factors supporting the unchanged view. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share, planned for distribution in 2025.
Mise à jour du récit Mar 10

CRBN: Special Dividend And Stronger Margins Will Support A More Optimistic Outlook

Analysts have trimmed their price target on Corbion from €24.60 to about €24.17, reflecting updated views on its projected revenue growth, profit margins, and future P/E assumptions. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share for 2025, which may influence your expected cash returns from holding the stock (Key Developments).
Mise à jour du récit Feb 24

CRBN: Higher Future P/E Assumptions Will Support A More Optimistic Outlook

Analysts have raised their price target on Corbion from about €22.73 to €24.60, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E levels. Valuation Changes Fair Value: Updated estimate increased from about €22.73 to €24.60 per share.
Mise à jour du récit Feb 09

CRBN: Buyback And Higher Discount Rate Will Pressure Overvalued Shares

Analysts have kept their price target on Corbion steady at €18.60, citing only small adjustments to assumptions around the discount rate, revenue trends, profit margins and future P/E as the basis for this unchanged view. What's in the News Corbion completed a share buyback program, repurchasing 577,615 shares for €10 million, equal to 0.99% of the company.
Mise à jour du récit Jan 26

CRBN: Higher Future P/E And Execution Risks Will Shape EUR 18 Outlook

Narrative Update on Corbion Analysts have raised their fair value estimate for Corbion to €18.60 from €18.00. This reflects updated views on discount rates, long term revenue trends, profit margins, and a higher future P/E assumption, alongside recent Street research where a key price target moved to €18 from €16.50.
Article d’analyse Jan 14

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it saw a double-digit share price rise of over 10...
Mise à jour du récit Jan 11

CRBN: Future P/E Reset And Margin Assumptions Will Shape EUR 18 Outlook

Analysts have raised their price target for Corbion to €18 from €16.50, citing updated assumptions on revenue trends, margins and future P/E as the main factors behind the change. Analyst Commentary The revised €18 price target still comes with a Hold stance, which signals a measured view on Corbion.
Mise à jour du récit Dec 26

CRBN: Higher EUR 18 Outlook Will Test Margin Delivery Amid Muted Demand

Analysts have raised their fair value estimate for Corbion to EUR 18 from EUR 14, reflecting increased confidence in the company’s profit margin outlook and a willingness to apply a higher future earnings multiple despite more muted revenue growth expectations. Analyst Commentary Bearish analysts acknowledge the higher fair value estimate but continue to highlight a cautious stance on Corbion’s near term prospects, emphasizing that the improved target largely reflects valuation mechanics rather than a fundamental re-rating of the growth outlook.
Mise à jour du récit Dec 12

CRBN: Margin Improvements And Buybacks Will Support A Future Re-Rating

Analysts have lowered their fair value price target on Corbion to EUR 30.00 from EUR 31.90, citing tempered expectations for long term revenue growth and profit margins, even as some recent Street research has modestly raised nearer term share price targets. Analyst Commentary Bullish analysts highlight that the recent upward revision in near term price targets, even from a relatively low base, reflects growing confidence that Corbion can stabilize its earnings profile and execute on margin improvement initiatives.
Article d’analyse Nov 14

Corbion N.V. (AMS:CRBN) Shares Could Be 35% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €28.50 Current share price of...
Article d’analyse Jun 23

Corbion N.V.'s (AMS:CRBN) Intrinsic Value Is Potentially 65% Above Its Share Price

Key Insights The projected fair value for Corbion is €30.72 based on 2 Stage Free Cash Flow to Equity Current share...
Article d’analyse May 07

Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely

Key Insights Corbion's Annual General Meeting to take place on 14th of May Salary of €725.0k is part of CEO Olivier...
Article d’analyse Apr 10

At €17.39, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?

Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw significant share price movement during recent...
Article d’analyse Mar 26

Corbion's (AMS:CRBN) Earnings May Just Be The Starting Point

Corbion N.V.'s ( AMS:CRBN ) earnings announcement last week was disappointing for investors, despite the decent profit...
User avatar
Nouveau récit Mar 02

Expanding Into Natural Antioxidants And Efficiency Improvements Will Drive Future Success

Strategic initiatives and operational optimizations are expected to significantly enhance EBITDA margins and net margins.
Article d’analyse Feb 28

Here's What To Make Of Corbion's (AMS:CRBN) Decelerating Rates Of Return

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Article d’analyse Dec 18

Risks To Shareholder Returns Are Elevated At These Prices For Corbion N.V. (AMS:CRBN)

It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 15.8x right now seems...
Article d’analyse Nov 18

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it received a lot of attention from a substantial price...
Article d’analyse Oct 31

An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €31.60 Corbion's €23.28 share...
Article d’analyse Sep 26

Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Jul 18

The Price Is Right For Corbion N.V. (AMS:CRBN)

It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 16.1x right now seems...
Article d’analyse Jun 20

Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €25.18 Corbion is estimated to...
Article d’analyse May 08

Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely

Key Insights Corbion will host its Annual General Meeting on 15th of May Salary of €713.0k is part of CEO Olivier...
Article d’analyse Apr 17

Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse Jan 20

Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is Lacking

There wouldn't be many who think Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 14.3x is worth a...
Article d’analyse Dec 18

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...
Article d’analyse Nov 04

Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €15.91 Corbion's €17.30 share...
Article d’analyse Sep 13

Corbion (AMS:CRBN) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Article d’analyse Aug 04

Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...
Article d’analyse Jul 14

When Should You Buy Corbion N.V. (AMS:CRBN)?

While Corbion N.V. ( AMS:CRBN ) might not be the most widely known stock at the moment, it received a lot of attention...
Article d’analyse Jun 04

Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value Estimate

Key Insights The projected fair value for Corbion is €21.22 based on 2 Stage Free Cash Flow to Equity Current share...
Article d’analyse Apr 21

Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Article d’analyse Mar 10

Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56

Corbion N.V. ( AMS:CRBN ) has announced that it will pay a dividend of €0.56 per share on the 30th of May. The dividend...
Article d’analyse Feb 22

Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?

Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it received a lot of attention from a substantial...
Article d’analyse Jan 26

Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
Article d’analyse Dec 20

Is Corbion (AMS:CRBN) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Article d’analyse Nov 24

Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)

Today we will run through one way of estimating the intrinsic value of Corbion N.V. ( AMS:CRBN ) by taking the expected...
Article d’analyse Nov 09

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...
Article d’analyse Oct 08

Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital Effectively

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Rendement pour les actionnaires

CRBNNL ChemicalsNL Marché
7D-2.3%1.7%1.6%
1Y-0.2%-25.9%26.8%

Rendement vs Industrie: CRBN a dépassé le secteur Dutch Chemicals qui a rapporté -25.9 % au cours de l'année écoulée.

Rendement vs marché: CRBN a sous-performé le marché Dutch qui a rapporté 26.8 % au cours de l'année écoulée.

Volatilité des prix

Is CRBN's price volatile compared to industry and market?
CRBN volatility
CRBN Average Weekly Movement4.1%
Chemicals Industry Average Movement4.1%
Market Average Movement4.7%
10% most volatile stocks in NL Market7.5%
10% least volatile stocks in NL Market2.8%

Cours de l'action stable: CRBN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Dutch.

Volatilité au fil du temps: La volatilité hebdomadaire de CRBN ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
19032,410Olivier Rigaudwww.corbion.com

Corbion N.V. fournit de l'acide lactique et des dérivés de l'acide lactique, des solutions de conservation des aliments, des mélanges fonctionnels et des ingrédients à base d'algues aux Pays-Bas, aux États-Unis, en Asie, dans le reste de l'Amérique du Nord, dans le reste de l'Europe, au Moyen-Orient et en Afrique. Elle opère à travers les segments Ingrédients et solutions fonctionnels et Santé et nutrition. La société propose des solutions alimentaires pour l'acidification, la rétention des couleurs, la décontamination, la sécurité alimentaire et la conservation, la fraîcheur et la durée de conservation, la santé et la nutrition, le renforcement du conditionnement, et le goût et la texture ; Purasorb R&D, une solution qui offre une gamme d'options de synthèse personnalisées ; des solutions de spécialités biochimiques, telles que la solvabilité, l'antimicrobien, l'hydratation, et la pharmacie ; et des solutions d'ingrédients à base d'algues, y compris le remplacement de l'huile de poisson et l'approvisionnement durable en oméga-3.

Corbion N.V. Résumé des fondamentaux

Comment les bénéfices et les revenus de Corbion se comparent-ils à sa capitalisation boursière ?
CRBN statistiques fondamentales
Capitalisation boursière€1.08b
Bénéfices(TTM)€74.80m
Recettes(TTM)€1.27b
14.5x
Ratio P/E
0.9x
Ratio P/S

Le site CRBN est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
CRBN compte de résultat (TTM)
Recettes€1.27b
Coût des recettes€932.70m
Marge brute€334.70m
Autres dépenses€259.90m
Les revenus€74.80m

Derniers bénéfices déclarés

Dec 31, 2025

Prochaine date de publication des résultats

Jul 31, 2026

Résultat par action (EPS)1.30
Marge brute26.41%
Marge bénéficiaire nette5.90%
Ratio dettes/capitaux propres53.8%

Quelles ont été les performances à long terme de CRBN?

Voir les performances historiques et les comparaisons

Dividendes

3.4%
Rendement actuel des dividendes
50%
Ratio de distribution

Le site CRBN verse-t-il des dividendes fiables ?

Voir CRBN l'historique des dividendes et les indices de référence
Quand faut-il acheter CRBN pour recevoir un dividende à venir ?
Corbion dates des dividendes
Date ex-dividendeMay 15 2026
Date de paiement du dividendeMay 22 2026
Jours jusqu'au dividende Ex6 days
Jours jusqu'à la date de paiement du dividende1 day

Le site CRBN verse-t-il des dividendes fiables ?

Voir CRBN l'historique des dividendes et les indices de référence

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 07:26
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Corbion N.V. est couverte par 13 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Setu ShardaBarclays
Sebastian BrayBerenberg
Fintan RyanBerenberg